SERT-to-DAT ratios in early parkinson's disease do not correlate with the development of dyskinesias

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-7

  Suwijn, Sven R ^a   Berendse, Henk W ^b   Verschuur, Constant V M ^a   Winogrodzka, Ania ^c   de Bie, Rob M A ^a   Booij, Jan ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Medical Centre Alkmaar   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Age of onset; Dopamine transporter; Dyskinesias; Parkinson's disease; Serotonin transporter

Indexed keywords

BETA CARBOXYMETHYOXY 3 BETA (4 IODOPHENYL) TROPANE I 123; DOPAMINE TRANSPORTER; LEVODOPA; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DYSKINESIA; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84881237888     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-44     Document Type: Article

References (34)

1. de Lau LM, Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
2. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM: Treatment of parkinsonism with levodopa. Arch Neurol 1969, 21:343-354.
3. Fahn S, Calne DB: Considerations in the management of parkinsonism. Neurology 1978, 28:5-7.
4. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000, 69:308-312.
5. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
6. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE: Levodopaassociated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006, 63:205-209.
7. Michelsen KA, Prickaerts J, Steinbusch HW: The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res 2008, 172:233-246.
8. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y: Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
9. Hirsch EC, Orieux G, Muriel MP, Francois C, Feger J: Nondopaminergic neurons in Parkinson's disease. Adv Neurol 2003, 91:29-37.
10. Carta M, Carlsson T, Kirik D, Bjorklund A: Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130:1819-1833.
11. Birkmayer W, Birkmayer JD: Dopamine action and disorders of neurotransmitter balance. Gerontology 1987, 33:168-171.
12. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I: Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 1994, 667:295-299.
13. Ng KY, Colburn RW, Kopin IJ: Effects of L-dopa on efflux of cerebral monoamines from synaptosomes. Nature 1971, 230:331-332.
14. Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M: Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
15. Eskow KL, Gupta V, Alam S, Park JY, Bishop C: The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 2007, 87:306-314.
16. Carlsson T, Carta M, Munoz A, Mattsson B, Winkler C, Kirik D, Björklund A: Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
17. Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P: Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord 2011, 26:1997-2003.
18. Boja JW, Cadet JL, Kopajtic TA, Lever J, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Carroll FI: Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl) tropane-2 betacarboxylic acid isopropyl ester. Mol Pharmacol 1995, 47:779-786.
19. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ: What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
20. Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW: Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging 2005, 32:689-695.
21. Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, Wolters EC: Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 1998, 245:14-20.
22. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, Neumeister A, Praschak-Rieder N, Angelberger P, Brücke T: Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000, 41:36-44.
23. Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA: AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging 2008, 35:1350-1356.
24. 123I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005, 30:996-1005.
25. Innis RB, Cunningham VJ, Delforge J, Fuijita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF: Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27:1533-1539.
26. Levy G, Louis ED, Cote L, Perez M, Mejia-Santana H, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Marder K: Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005, 62:467-472.
27. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P: Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010, 40:216-221.
28. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA: Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008, 28:441-444.
29. Brooks DJ, Ibanez V, Sawle GV, Quinn NP, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS: Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990, 28:547-555.
30. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z: Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003, 60:1223-1229.
31. Strecker K, Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O: Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter. J Neurol 2011, 258:19-26.
32. 123I]ADAM in healthy young adults. Nucl Med Biol 2006, 33:185-191.
33. Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J: Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med 2012, 57:1087-1090.
34. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB: N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994, 37:1558-1561.